Systemic oncological therapy in breast cancer patients on dialysis.

Autor:	Khan S; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States. skhan114@northwell.edu., Araji G; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., Yetiskul E; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., Keesari PR; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., Haddadin F; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., Khamis Z; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., Chowdhry V; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., Niazi M; Department of Hematology and Oncology, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., Afif S; Department of Internal Medicine, CUNY School of Medicine, New York, NY 10031, United States., Dhar M; Department of Hematology and Oncology, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States., El-Sayegh S; Department of Internal Medicine, Northwell Health - Staten Island University Hospital, Staten Island, NY 10305, United States.
Jazyk:	angličtina
Zdroj:	World journal of clinical oncology [World J Clin Oncol] 2024 Jun 24; Vol. 15 (6), pp. 730-744.
DOI:	10.5306/wjco.v15.i6.730
Abstrakt:	The advancement of renal replacement therapy has significantly enhanced the survival rates of patients with end-stage renal disease (ESRD) over time. However, this prolonged survival has also been associated with a higher likelihood of cancer diagnoses among these patients including breast cancer. Breast cancer treatment typically involves surgery, radiation, and systemic therapies, with approaches tailored to cancer type, stage, and patient preferences. However, renal replacement therapy complicates systemic therapy due to altered drug clearance and the necessity for dialysis sessions. This review emphasizes the need for optimized dosing and administration strategies for systemic breast cancer treatments in dialysis patients, aiming to ensure both efficacy and safety. Additionally, challenges in breast cancer screening and diagnosis in this population, including soft-tissue calcifications, are highlighted. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu